Osteoporosis in chronic liver disease

Area of Science:

• Hepatology
• Endocrinology
• Bone Biology

Background:

• Osteoporosis is a significant complication in chronic liver disease (CLD), particularly in advanced stages, chronic cholestasis, non-alcoholic fatty liver disease, hemochromatosis, and alcoholism.
• The exact mechanisms driving osteoporosis in CLD are not fully elucidated, but a primary factor appears to be diminished bone formation.

Purpose of the Study:

• To explore the multifactorial mechanisms contributing to decreased bone formation and increased resorption in patients with chronic liver disease.
• To investigate the roles of specific molecular pathways and substances implicated in CLD-associated bone disorders.

Main Methods:

• Review of existing literature on osteoporosis in chronic liver disease.
• Analysis of the potential impact of sclerostin and the Wnt/β-catenin pathway on bone formation.
• Consideration of the effects of cholestasis, iron, alcohol, and inflammation on bone metabolism.

Main Results:

• Reduced bone formation is a key feature of osteoporosis in CLD, influenced by sclerostin and the Wnt/β-catenin pathway.
• Retained substances in cholestasis (bilirubin, bile acids), iron, and alcohol can directly impair osteoblastic cells.
• Proinflammatory cytokines may play a role, and increased bone resorption can occur in advanced cholestatic liver disease.

Conclusions:

• Osteoporosis in CLD results from complex interactions, primarily low bone formation, influenced by molecular regulators and disease-specific toxins.
• Low vitamin D, poor nutrition, and hypogonadism are additional contributing factors to the bone pathology observed in CLD patients.